Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Endothelial dysfunction is a predictive risk factor for the development of atherosclerosis and is assessed by flow-mediated dilation (FMD). Although it is known that NO-dependent endothelial dysfunction occurs after consuming a high-fat meal, the magnitude of the effect and the factors that affect the response are unquantified.
Objectives: We conducted a systematic review and meta-analysis exploring the quantitative effects of a single high-fat meal on endothelial function and determined the factors that modify the FMD response.
Methods: Six databases were systematically searched for original research published up to January 2022. Eligible studies measured fasting and postprandial FMD following consumption of a high-fat meal. Meta-regression was used to analyze the effect of moderator variables.
Results: There were 131 studies included, of which 90 were suitable for quantitative meta-analysis. A high-fat meal challenge transiently caused endothelial dysfunction, decreasing postprandial FMD at 2 hours [-1.02 percentage points (pp); 95% CI: -1.34 to -0.70 pp; P < 0.01; I2 = 93.3%], 3 hours [-1.04 pp; 95% CI: -1.48 to -0.59 pp; P < 0.001; I2 = 84.5%], and 4 hours [-1.19 pp; 95% CI: -1.53 to -0.84 pp; P < 0.01; I2 = 94.6%]. Younger, healthy-weight participants exhibited a greater postprandial reduction in the FMD percentage change than older, heavier, at-risk groups after a high-fat meal ( P < 0.05). The percentage of fat in the meals was inversely associated with the magnitude of postprandial changes in FMD at 3 hours (P < 0.01).
Conclusions: A single, high-fat meal adversely impacts endothelial function, with the magnitude of the impact on postprandial FMD moderated by the fasting FMD, participant age, BMI, and fat content of the meal. Recommendations are made to standardize the design of future postprandial FMD studies and optimize interpretation of results, as high-fat meals are commonly used in clinical studies as a challenge to assess endothelial function and therapeutics. This trial was registered at PROSPERO as CRD42020187244.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437993 | PMC |
| http://dx.doi.org/10.1093/ajcn/nqac153 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alleviating effects of polyphenol extract from rapeseed meal on type 2 diabetes in mice via modulation of gut microbiota and AMPK/mTOR signaling pathways.
Food Res Int
November 2025
Oil Crops Research Institute of the Chinese Academy of Agricultural Sciences, Oil Crops and Lipids Process Technology National & Local Joint Engineering Laboratory, Key Laboratory of Oilseeds Processing, Ministry of Agriculture and Rural Affairs, Hubei Key Laboratory of Lipid Chemistry and Nutrition
Type 2 diabetes mellitus (T2DM) is a a complex metabolic disorder that poses a serious threat to human health. Although polyphenol extract from rapeseed meal (RMP) has demonstrated inhibitory activity against α-glucosidase, the alleviating effects on T2DM and the underlying molecular mechanisms remain largely unexplored in T2DM. In this study, the antidiabetic effects of RMP were investigated using a T2DM mouse model induced by a high-fat diet (HFD) combined with streptozotocin (STZ) administration.
View Article and Find Full Text PDFEffects of Brown Rice, Meal Replacements, and Anti-Obesity Drugs on Mitochondria in Obese Rats.
Diabetes Metab Syndr Obes
September 2025
School of Medical, Indigenous and Health, University of Wollongong, Wollongong, New South Wales, Australia.
Introduction: Obesity remains a critical global health challenge, intricately linked to poor dietary quality, gut microbiota dysbiosis, and mitochondrial dysfunction.
Purpose: This study aimed to investigate the comparative effects of brown rice, meal replacements, and thiazolidinediones on mitochondrial abundance and gut microbiota composition in a rat model of diet-induced obesity.
Methods And Materials: A total of twenty male Sprague Dawley rats were randomly assigned to five groups: control, high-fat high-fructose diet, and three intervention groups receiving the same obesogenic diet supplemented with brown rice, meal replacement, or thiazolidinediones for twelve weeks.
Utilization of intravenous posaconazole in pediatric patients undergoing hematopoietic stem cell transplant.
Transplant Cell Ther
September 2025
Division of Pharmacy, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Background: Pediatric patients undergoing hematopoietic stem cell transplant (HSCT) are at high risk for fungal infections including Candida, Aspergillus, and Mucorales necessitating the use of broad-spectrum antifungal agents such as posaconazole for prophylaxis and at times for treatment of invasive fungal infections. When first approved, posaconazole was limited to an immediate release oral suspension, which exhibited unreliable absorption dependent on co-administration with high fat meals. During HSCT, patients commonly have significant nausea, vomiting, and decreased enteral intake making this formulation particularly challenging.
View Article and Find Full Text PDFSafety and pharmacokinetics evaluation of oroxylin A in Chinese healthy volunteers: a phase I, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect study.
Clin Transl Oncol
September 2025
Clinical Pharmacology Research Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Purpose: Oroxylin A (OA) is a flavonoid, obtained from the root of Scutellaria baicalensis Georgi which is a traditional Chinese herbal, with antitumor and other pharmacological activities. OA tablets are an innovative drug, and a formal single ascending and multiple dose pharmacokinetic (PK) trial was conducted in humans to evaluate the required to determine the safety and tolerability of OA as well as the effect of food on its PK parameters profile.
Methods: This clinical study consisted of three parts: single ascending dose (400[n = 3], 800, 1600 and 2400 mg OA [n = 8/group] and placebo [n = 6]), multiple dose (1600 or 2400 mg OA [n = 8 / group] and placebo [n = 4] once daily), and food effects (1600 mg OA single dose [n = 12]).
Relative Bioavailability, Food Effect, and Bioequivalence Studies to Assess a New Zanubrutinib 160-mg Tablet: Results From 2 Phase 1 Studies in Healthy Volunteers.
Clin Pharmacol Drug Dev
September 2025
Clinical Pharmacology & Pharmacometrics, BeOne Medicines Ltd, San Carlos, CA, USA.
Zanubrutinib is a next-generation Bruton tyrosine kinase inhibitor approved for treating B-cell malignancies. Two phase 1 studies evaluated a new 160-mg zanubrutinib tablet versus 80-mg capsules. In study BGB-3111-115 (n = 43), a randomized 3-period crossover trial, relative bioavailability and food effects were assessed.
View Article and Find Full Text PDF